Public warned vs fake Centrum tablets-A A +A
Saturday, October 19, 2013
MANILA -- The Food and Drug Administration (FDA) warned the public on Saturday against the presence of counterfeited Centrum and Centrum Silver tablets that are currently being sold on-line.
In an advisory, the FDA said they found counterfeit versions of the multivitamins + mineral tablets produced by Pfizer Consumer Healthcare (PCH).
"The FDA monitored counterfeit multivitamins + mineral tablets that are being advertised, sold or offered for sale on-line thru Beeconomic Philippines, Inc., owned and operated by GROUPON Philippines," the advisory stated.
It noted that the counterfeit Centrum tablets were found to be without the FDA Certificate of Product Registration Number and do not contain the same formulation approved by the FDA; do not carry the complete name and address of the manufacturer and/or distributor as required by the FDA; and that the font size of the generic name "multivitamin + mineral" is not in conformity with the labeling requirements that the generic name should at least be one point size bigger than the brand name.
"The products are counterfeit as defined by Republic Act 8203 (Special Law on Counterfeit Drugs)," said the FDA.
On the other hand, the FDA said the establishments are violating the provisions of RA 9711, otherwise known as the FDA Act of 2009, which prohibits the manufacture, importation, exportation, sale, offering for sale, distribution, transfer, or retail of any drug product by any natural juridical person without the License to Operate (LTO) from the FDA.
"The FDA warns the public from buying medicines on-line until such time that the FDA can assure the safety, efficacy and quality of medicines sold through this medium," said FDA.
And with the said finding, the agency is strongly urging the public to buy their medicines only from FDA-licensed establishments and outlets.
In addition, consumers are being advised to check the labels of the medicines they are buying as documentation and traceability are vital to post-market surveillance and investigation in cases of adverse drug reactions.
The FDA also said it would be best to avoid illegitimate drug outlets, which are not supervised by registered or licensed pharmacists. (HDT/Sunnex)